期刊文献+

基因多态性对华法林个体化药量作用的临床分析 被引量:2

Effects of gene polymorphisms on individual warfarin dose
下载PDF
导出
摘要 目的探讨细胞色素氧化酶P450(CYP2C9)和环氧化物还原酶复合体(VKORC1)基因型与华法林个体化剂量的关系。方法应用PCR-RFLP方法,检测临床长期口服华法林患者(362例)的VKORC1-1639及CYP2C9-1061A/C多态性,并按其基因型分组,分别比较VKORC1和CYP2C9不同基因型间的平均华法林剂量。结果病例检测出VKORC1-1639 AA基因型273例(75.4%)、AC基因型81例(22.3%)及CC基因型8例(2.3%)。CYP2C9基因检测AA型321例(88.7%)、AG基因型34例(9.5%)、GG型7例(1.8%)。两组VKORC1和CYP2C9各基因型分布差异无统计学意义(P>0.05)。VKORC1不同基因型间患者所需华法林平均剂量GA、GG组明显高于AA组(P<0.01)。携带CYP2C9基因型的患者(AG+GG)组华法林平均剂量要低于AA组(P<0.05)。结论华法林应用剂量偏低可能与VKORC G-C和CYP2C9 A-G转变有关。VKORC1 AA型占多数可能是中国汉族人群所需华法林剂量普遍较低的重要原因。 Objective To investigate the quantitative influence of cytochrome P4502C9(CYP2C9)and epoxide reductase complex subunit 1(VKORC1)polymorphisms on warfarin dose requirements.Methods 362 patients taking warfarin were enrolled in the study.PCR-RFLP technique was used to genotype the CYP2C9-1061A/C and VKORC1-1639 polymorphism in warfarin-treated patients.The mean warfarin doses used for the patients with different VKORC1 and CYP2C9 genotypes were compared.Results The frequencies of the VKORC1-1639 AA,AG,GG genotypes of patients were 75.4%,22.3% and 2.3% respectively;frequencies of the CYP2C9-1061 AA,AC,CC genotypes of patients were 88.7%,9.5% and 1.8% respectively.There was no significant difference in genotype distribution of VKORC1-1639 and CYP2C9-1061 between the patients and the healthy controls(P0.05).The mean warfarin dose differed significantly among the VKORC1 genotypes(P0.001);the patients carrying VKORC1-1639 AA genotypes had a lower mean warfarin dose than those carrying AG genogype(P0.05),and the mean warfarin dose of the patients with AG genotype was lower than those with GG genotype(P0.05).The carriers of CYP2C9-1061 C allel(AC+CC)had a lower warfarin dose than those with CYP2C9-1061 AA genotype(P0.05).Conclusion There might be an association between VKORC1-1639 G-A,CYP2C9-1061 A-C transformation and decreased warfarin dose,and the major genotype of VKORC1-1639(AA)might be the reason for the universally lower warfarin dosage used in Chinese Han population.
出处 《实用药物与临床》 CAS 2012年第4期196-198,共3页 Practical Pharmacy and Clinical Remedies
关键词 华法林 基因多态性 给药模型 Warfarin Gene polymorphism Dosage model
  • 相关文献

参考文献14

  • 1Sullivan-klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism [ J ]. Phamacogenetice, 1996,6 : 341-349.
  • 2Rost S ,Fregin A,Ivaskevicius V,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 [J]. Nature ,2009,427:537-541.
  • 3Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K peroxide reductase[J]. Nature,2008,427:541-544.
  • 4Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term,lowintensity warfarin therapy for the prevention of recurrent ve- nous thromboembolism [ J ]. N Engl J Med, 2009,348 : 1425-1434.
  • 5孙艺红,胡大一.华法林对中国人心房颤动患者抗栓的安全性和有效性研究[J].中华内科杂志,2004,43(4):258-260. 被引量:170
  • 6Sconece EA, Khan Ti, Wynne HA,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen [J]. Blood, 2010,106 ( 7 ) : 2329-2333.
  • 7Yu HC, Chan TY, Critchley JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients [ J ]. QJM, 1996,89 : 127-135.
  • 8Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-nature [ J ]. Clin Pharmacol Ther, 2001,70 : 159-164.
  • 9Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype [J]. Pharmacogenetics ,2004,14 : 539-547.
  • 10Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin [J]. Clin Pharmacol Ther,2004,75:204-212.

二级参考文献9

  • 1Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the
  • 2Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001,119(1 Suppl):8S-21S.
  • 3Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest, 2001,119(1 Suppl):108S-121S.
  • 4The stroke prevention in atrial fibrillation investigation. Bleeding during antithrombotic thearapy in patients with atrial fibrillation. Arch Intern Med, 1996, 156:409-416.
  • 5Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med, 1996,124:970-979.
  • 6Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med,1994,120:897-902.
  • 7Stroke prevention in atrial fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation Ⅲ randomized clinic trial. Lan
  • 8Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of reccurrent venous thromboembolism. N Engl J Med, 2003,348:1425-1434.
  • 9胡大一,孙艺红,周自强,李奎宝,倪永斌,杨光,孙淑红,李蕾.中国人非瓣膜性心房颤动脑卒中危险因素的病例-对照研究[J].中华内科杂志,2003,42(3):157-161. 被引量:361

共引文献169

同被引文献29

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部